Abstract
The most devastating aspect of cancer is the propensity of malignant cells to spread from a primary site to distant organs, where new lesions develop. Indeed, the majority of deaths from cancer are attributed to the continued proliferation of metastases that are resistant to conventional therapeutics. There are several reasons for the failure of treatment for established metastasis. By the time of diagnosis of primary tumors, metastasis may have already occurred, but the lesions are often too small to be detected. Second, the anatomic location of many metastases may limit the effective dose of therapeutic agents that can be delivered to the lesions without being toxic to normal tissues. The third, and most formidable, problem is the heterogeneous nature of malignant neoplasms, which leads to the rapid biological diversification of tumor cells and to the development of resistance to conventional therapy (1,2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Poste, G., and Fidler, I.J. Nature 283:139–146, 1979.
Fidler, I.J., and Hart, I.R. Science 217:998–1003, 1982.
Fidler, I.J., and Kripke, M.L. Science 197:893–895, 1977.
Talmadge, J.E., Wolman, S.R., and Fidler, I.J. Science 217:361–363.
Poste, G., Tzeng, J., Doll, J., Greig, R., Reiman, D., and Zeidman, I. Proc. Natl. Acad. Sci. USA, 79:6574–6579, 1982.
Talmadge, J.E., Benedict, K., Madsen, J., and Fidler, I.J. Cancer Res. 44:3801–3805, 1984.
Poste, G., Doll, J., and Fidler, I.J. Proc. Natl. Acad. Sci. USA 78:6226–6230, 1981.
Cifone, M.A., and Fidler, I.J. Proc. Natl. Acad. Sci. U.S.A. 78:6949–6952, 1981.
Bosslet, K. and Schirrmacher, V. Int. J. Cancer 29:195–202, 1982.
Harris, J.F., Chambers, A.F., Hill, R.P., and Ling, V. Proc. Natl. Acad. Sci. U.S.A. 79:5547–5551, 1982.
Fidler, I.J., and Poste, G. Springer Semin. Immunopathol. 5:161–174, 1982.
Fidler, I.J. Lymphokine Res. 3:51–54, 1984.
Tanaka, Y., and Schroit, A. J. Biol. Chem. 258:11335–11343, 1983.
Hibbs, J.B. Jr. JNCI 53:1487–1492, 1974.
Norbury, K.C., and Kripke, M.L. J. Reticuloendothel. Soc. 26:827–837, 1979.
Fidler, I.J. Cancer Res. 34:1074–1078, 1974.
Liotta, L.A., Gattozzi, C., Kleinerman, J., et al., Br. J. Cancer 36:639–641, 1977.
Chedid, L., Carelli, L., and Audibert, F. Reticuloendothel. Soc. 26:631–641, 1979.
Fidler, I.J., and Raz, A. In: Lymphokines (Ed. E. Pick), Academic Press, Inc., New York, Volume 3, 1981, pp. 345–363.
Celada, A., Gray, P.W., Rinderknect, E., and Schreiber, R.D. J. Exp. Med. 160:55–62, 1984.
Kleinerman, E.S., Zicht, R., Sarin, P.S., Gallo, R.C. and Fidler, I.J. Cancer Res. 44:4470–4475, 1984.
Hibbs, J.B., Jr. Science 184:468–471, 1974.
Bucana, C., Hoyer, L.L., and Hobbs, B. et al. Cancer Res. 36:4444–4458, 1976.
Fidler, I.J., and Kleinerman, E.S. J. Clinical Oncol. 2:937–943, 1984.
Kleinerman, E.S., Erickson, K.L., Schroit, A.J., et al. Cancer Res. 43:2010–2014, 1983.
Fogler, W.E., and Fidler, I.J. Cancer Res. 45:14–18, 1985.
Giavazzi, R., Bucana, C.D., and Hart, I.R. JNCI 73:447–455, 1984.
Fidler, I.J., Gersten, D.M., and Budmen, M.B. Cancer Res. 36:3160–3165, 1976.
Hanna, N., and Fidler, I.J. JNCI 66:1183–1190, 1981.
Fidler, I.J., Roblin, R.O., and Poste, G. Cell. Immunol. 38:131–146, 1978.
Allison, A.C. J. Reticuloendothel. Soc. 26:619–630, 1979.
Lederer, E. J. Med. Chem. 23:819–825, 1980.
Parant, M., Parant, F., and Chedid, L. et al. Int. J. Immunopharmacol. 1:35–41, 1979.
Sone, S., and Fidler, I.J. Cell Immunol. 57:42–50, 1981.
Schroit, A.J., Hart, I.R., Madsen, J. and Fidler, I.J. J. Biol. Response Modifiers 2:97–100, 1983.
Poste, G., Kirsh, R., and Fidler, I.J. Cell Immunol. 44:71–88, 1979.
Poste, G., and Kirsh, R. Cancer Res. 39:2582–2590, 1979.
Fidler, I.J., and Fogler, W.E. Lymphokine Res. L:73–77, 1982.
Fidler, I.J. J. Immunol. 127:1719–1720, 1981.
Snyderman, R., Pike, M.C., Blaylock, B.L. and Weinstein, P. J. Immunol. 116:585–589, 1976.
Sone, S. and Fidler, I.J. Cancer Res. 41:2401–2406.
Xu, Z.L. and Fidler, I.J. Cancer Immunol. Immunother. 18:118–122, 1984.
Hart, I.R. Am. J. Pathol. 97:587–600, 1979.
Hart, I.R., Fogler, W.E., Poste, G., et al. Cancer Immunol. Immunother. 10:157–166, 1981.
Fidler, I.J., Raz, A., Fogler, W.E., et al. Cancer Res. 40:4460–4466, 1980.
Schroit, A.J., and Fidler, I.J. Cancer Res. 42:1616–1617, 1982.
Griswold, D.P., Jr. Cancer Chemother. Rep. 3:315–323, 1972.
Deodhar, S.D., Barna, B.P., Edinger, M., et al. J. Biol. Response Modifiers 1:27–34, 1982.
Lopez Berestein, G., Milas, L., Hunter N., Mehta, K., Eppstein, D., Van der Pas, M.A., Mathews, T.R., and Hersh, E.M. Clin, Exp. Met. 2:366–377, 1984.
Phillips, N.C., Moras, M.L., Chedid, L., Lefrancier, P., and Bernard, J.M. Cancer Res. 45:128–134, 1985.
Fidler, I.J., and Schroit, A.J. J. Immunol. 133:515–519, 1984.
Fidler, I.J., Barnes, Z., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. Cancer Res. 42:496–501, 1982.
Key, M.E., Talmadge, J.E. Fogler, W.E., Bucana, C., and Fidler, I.J. JNCI 69:1189–1198, 1982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Fidler, I.J. (1986). The Recognition and Destruction of Metastatic Cells by Tumoricidal Macrophages. In: Lapis, K., Liotta, L.A., Rabson, A.S. (eds) Biochemistry and Molecular Genetics of Cancer Metastasis. Developments in Oncology, vol 41. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2299-3_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2299-3_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9416-0
Online ISBN: 978-1-4613-2299-3
eBook Packages: Springer Book Archive